MedTrace Logo

Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders

NCT05791851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2023-03-30

No results posted yet for this study

Summary

The goal of this natural history study is to examine the immune responses to the Heplisav-B vaccine in Veterans living with HIV who were non-responders to prior HBV vaccination. A comparison group of HBV vaccine nonresponders without HIV infection will be enrolled to characterize the HIV-associated immune alterations that affect vaccine response. The investigators hypothesize that TLR9-mediated innate immune stimulation with Heplisav will elicit HBV seroprotection despite prior vaccination failures in persons living with HIV, compared to HIV uninfected individuals.

Participants eligible for Heplisav-B vaccination will be asked to provide blood samples at multiple timepoints before and after their vaccination.

Conditions

Sponsors & Collaborators

  • Baltimore VA Medical Center

    collaborator FED

  • University of Maryland, Baltimore

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
109 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-23
Primary Completion
2022-06-14
Completion
2022-06-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05791851 on ClinicalTrials.gov